中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 6
Jun.  2010
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2010  >  26(6): 663-665

Recent status and prospect of ascites treatment in cirrhosis patients

  • Published Date: 2010-06-20
    Abstract
  • Ascites is the most common complication in cirrhosis, and is closely related to the increased mortality due to infection, diluted hyponatremia and renal failure.Rest and sodium restriction are the components of the managements of uncomplicated mild ascites.Low dose diuretics are effective in patients with moderate ascites.Furthermore, the large-volume paracentesis (LVP) with albumin administration (8 g/L of ascites removed) are the treatment of choice for the management of patients with large ascites.As to the refractory ascites, methods for treatment include repeated LVP with plasma expander or transjugular intrahepatic portosystemic shunt (TIPS) .New medicines such as vasoconstrictors and V2-receptors of vasopressin maybe beneficial in patients with ascites in liver cirrhosis.

     

    • FullText(HTML)
    • References(19)
  • [1]Planas R, Montoliu S, Balleste'B, et al.Natural history of patients hospitalized for management of cirrhotic ascites[J].Clin Gastroenterol Hepatol, 2006, 4 (11) ∶1385-1394.
    [2]Gine`s P.Vaptans:a promising therapy in the management of advanced cirrhosis[J].J Hepatol, 2007, 46 (6) ∶1150-1152.
    [3]Moore KP, Wong F, Gine`s P, et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology, 2003, 38 (1) ∶258-266.
    [4]Santos J, Planas R, Pardo A, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis:a randomized comparative study of efficacy and safety[J].J Hepatol, 2003, 39 (2) ∶187-192.
    [5]Li CP, Lee FY, Hwang SJ, et al.Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis:a randomized crossover study[J].Am J Gastroenterol, 2000, 95 (4) ∶1051-1055.
    [6]Lee FY, Lee SD, Tsai YT, et al.A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps[J].J Hepatol, 1991, 12 (2) ∶236-240.
    [7]Angeli P, Albino G, Carraro P, et al.Cirrhosis and muscle cramps:evidence of a causal relationship[J].Hepatology, 1996, 23 (2) ∶264-273.
    [8]Ruiz-del-Arbol L, Monescillo A, Jimeénez W, et al.Paracentesis-induced circulatory dysfunction:mechanism and effect on hepatic hemodynamics in cirrhosis[J].Gastroenterology, 1997, 113 (2) ∶579-586.
    [9]Runyon BA.Management of adult patients with ascites due to cirrhosis[J].Hepatology, 2004, 39 (3) ∶841-856.
    [10]Sakai H, Sheer TA, Mendler MH, et al.Choosing the location for non-image guided abdominal paracentesis[J].Liver Int, 2005, 25 (5) ∶984-986.
    [11]Moore KP, Aithal GP.Guidelines on the management of ascites in cirrhosis[J].Gut, 2006, 55 (Suppl6) ∶vi1-vi12.
    [12]Moore KP, Wong F, Gine`s P, et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology, 2003, 38 (1) ∶258-266.
    [13]Boyer TD, Haskal Z.The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension[J].Hepatology, 2005, 41 (2) ∶386-400.
    [14]Gine`s P, Uriz J, Calahorra B, et al.Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis[J].Gastroenterology, 2002, 123 (6) ∶18391847.
    [15]Salerno F, Camma C, Enea M, et al.Transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis of individual patient data[J].Gastroenterology, 2007, 133 (3) ∶825834.
    [16]Fernandez-Varo G, Ros J, Cejudo-Martin P, et al.Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites[J].J Hepatol, 2003, 38 (6) ∶755-761.
    [17]Wong F, Gine`s P, Watson HR, et al.Effects of a selective vasopressin V2receptor antagonist, satavaptan (SR121463B) , on recurrence of ascites after large volume paracentesis[J].Hepatology, 2006, 44 (2) ∶s270.
    [18]Kalambokis G, Fotopoulos A, Economou M, et al.Effects of a7day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites[J].J Hepatol, 2007, 46 (2) ∶213-221.
    [19]Lenaerts A, Codden T, Meunier JC, et al.Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system[J].Hepatology, 2006, 44 (4) ∶844849.
    • Relative Articles

  • Relative Articles

    [1]Lanjing WANG, Xin YAO, Jianping QIN, Shanhong TANG. TIPS for treatment of refractory ascites in cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2606-2610. doi: 10.3969/j.issn.1001-5256.2022.11.034
    [2]Lei WANG. Integrated traditional Chinese and Western medicine diagnosis and treatment of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2022, 38(9): 1956-1961. doi: 10.3969/j.issn.1001-5256.2022.09.002
    [3]Yu TIAN, Jia HONG, Bingqiong WANG, Hong YOU. Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites[J]. Journal of Clinical Hepatology, 2021, 37(1): 173-175. doi: 10.3969/j.issn.1001-5256.2021.01.037
    [5]Chen Yu, Zhou Li. Research advances in treatment of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2016, 32(6): 1069-1074. doi: 10.3969/j.issn.1001-5256.2016.06.009
    [6]Yu Yuan, Zhang JianLiang, Lu YunFei, Chen XiaoRong. Application of external treatment of traditional Chinese medicine in cirrhotic ascites[J]. Journal of Clinical Hepatology, 2016, 32(4): 781-784. doi: 10.3969/j.issn.1001-5256.2016.04.040
    [7]Fan ZhiDong, You JinLi. Diagnosis and treatment procedure for intractable liver ascites[J]. Journal of Clinical Hepatology, 2015, 31(3): 472-474. doi: 10.3969/j.issn.1001-5256.2015.03.039
    [8]Zhong HuaPing, Zhou Zhi, Liao GuiLan. Analysis of early warning indicators of tuberculous peritonitis in patients with cirrhotic ascites[J]. Journal of Clinical Hepatology, 2014, 30(4): 357-359. doi: 10.3969/j.issn.1001-5256.2014.04.017
    [9]Xie WeiFen, Ceng Xin. Controversial problems in management of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2014, 30(7): 601-603. doi: 10.3969/j.issn.1001-5256.2014.07.006
    [10]Zhu Peng, Wang YuMing. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012[J]. Journal of Clinical Hepatology, 2013, 29(9): 645-646. doi: 10.3969/j.issn.1001-5256.2013.09.002
    [11]Liu ChengHai, Xing Feng. The potential benefit managing ascites due to cirrhosis using an integrative medicine approach[J]. Journal of Clinical Hepatology, 2013, 29(4): 253-256.
    [12]Wu HaiQing, Wang Hui. Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J]. Journal of Clinical Hepatology, 2012, 28(9): 651-653.
    [13]Zeng Zhen, Xing Feng, Zhou AiMin, Tao YanYan, Liu ChengHai. Effect of Xiaozhang Tie on cirrhotic ascites and peritoneal vascular permeability in mice[J]. Journal of Clinical Hepatology, 2012, 28(9): 689-694.
    [14]Liu JianJun, Li Nan, Zhi Hong, Wu XiaoYing. Current clinical perspectives and implications of cirrhotic ascites in China[J]. Journal of Clinical Hepatology, 2012, 28(9): 701-703.
    [15]Shi HaiDong. Clinical observation of alprostadil injection in the treatment of liver cirrhosis with jaundice[J]. Journal of Clinical Hepatology, 2011, 27(9): 962-964.
    [16]Yuan ShanShan, Han GuoHong, Bo Ming, He ChuangYe, Yin ZhanXin, Wang JianHong, Qi XingShun, Yang ZhiPing, Zhang Wei. Prognostic factors in the prediction of survival following TIPS for cirrhosis and refractory ascites[J]. Journal of Clinical Hepatology, 2011, 27(5): 525-527.
    [17]Qiu Ling, Hu YuLin. Recent status and prospect of ascites treatment in cirrhosis patients[J]. Journal of Clinical Hepatology, 2010, 26(6): 663-665.
    [18]Zhan GuoQing, Tan HuaBing, Li RuGui, Du WeiXing, Li Gang, Zhu Lin. The efficacy of mannital combined with dopamine for the treatment of refractory ascites in cirrhosis[J]. Journal of Clinical Hepatology, 2009, 25(6): 424-426.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.4 %FULLTEXT: 3.4 %META: 87.9 %META: 87.9 %PDF: 8.8 %PDF: 8.8 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.4 %其他: 3.4 %China: 0.8 %China: 0.8 %India: 0.6 %India: 0.6 %Taiwan, China: 0.3 %Taiwan, China: 0.3 %[]: 0.3 %[]: 0.3 %上海: 2.0 %上海: 2.0 %北京: 6.5 %北京: 6.5 %南京: 0.3 %南京: 0.3 %南宁: 0.3 %南宁: 0.3 %台州: 0.3 %台州: 0.3 %台湾省: 0.3 %台湾省: 0.3 %吉林: 7.3 %吉林: 7.3 %宁波: 0.3 %宁波: 0.3 %密蘇里城: 0.3 %密蘇里城: 0.3 %广州: 0.3 %广州: 0.3 %张家口: 4.8 %张家口: 4.8 %昆明: 1.1 %昆明: 1.1 %杭州: 1.4 %杭州: 1.4 %武汉: 0.3 %武汉: 0.3 %沈阳: 0.3 %沈阳: 0.3 %济南: 0.3 %济南: 0.3 %深圳: 0.3 %深圳: 0.3 %湖州: 1.1 %湖州: 1.1 %漯河: 0.3 %漯河: 0.3 %烟台: 0.3 %烟台: 0.3 %石家庄: 0.6 %石家庄: 0.6 %芒廷维尤: 30.8 %芒廷维尤: 30.8 %芝加哥: 0.3 %芝加哥: 0.3 %莫斯科: 1.7 %莫斯科: 1.7 %衢州: 1.1 %衢州: 1.1 %西宁: 29.7 %西宁: 29.7 %金华: 1.1 %金华: 1.1 %长春: 1.4 %长春: 1.4 %其他ChinaIndiaTaiwan, China[]上海北京南京南宁台州台湾省吉林宁波密蘇里城广州张家口昆明杭州武汉沈阳济南深圳湖州漯河烟台石家庄芒廷维尤芝加哥莫斯科衢州西宁金华长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (444) PDF downloads(454) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2530]YesterdayPV[4969]TodayIP[415]TodayPV[621]Online[59]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return